Announcement • Jul 09

Heartflow to Announce Eight New Datasets from Clinical Studies Spanning More Than 36,000 Patients at the Society of Cardiovascular Computed Tomography

Heartflow, Inc. announced eight new datasets from clinical studies spanning more than 36,000 patients will be presented at the Society of Cardiovascular Computed Tomography (SCCT) 2026 Annual Scientific Meeting taking place July 9-12, 2026 in San Diego. Heartflow Plaque Staging, the only staging tool based on total plaque volume, is now included with every Heartflow Plaque Analysis. These studies reveal over 50% of symptomatic patients with zero coronary artery calcium harbor significant non-calcified plaque that traditional CAC scoring cannot detect. Heartflow Plaque Analysis with Heartflow Plaque Staging closes this gap. The new data show Heartflow’s technology comprehensively reclassifies risk, is highly reproducible, and remains consistent across scanner types. Heartflow announced the launch of Heartflow Plaque Staging, the only CAD staging tool based on total plaque volume, integrated into every Heartflow Plaque Analysis. Heartflow Plaque Staging is backed by the strongest data with up to 16 years of follow-up and prospectively demonstrated clinical utility. Every case now includes a Heartflow Plaque Stage—from mild to extensive—based on total plaque volume. Plaque Stages generate automatically in the Heartflow One platform’s User Interface and Structured Report, enabling seamless integration into existing clinician workflows. This allows clinicians to precisely risk stratify patients and confidently manage their care without delay. Key presentations include: DECIDE Registry (Poster 604): Heartflow Plaque Staging Reclassifies Risk Missed by Traditional Calcium Scoring. Symptomatic patients with zero CAC scores can remain at substantial risk from non-calcified (soft) plaque that calcium scoring cannot detect. This DECIDE Registry sub-study of 11,792 symptomatic patients quantifies this diagnostic challenge and demonstrates how total plaque volume-based Heartflow Plaque Staging delivers a precise solution. Half of all patients presenting with a CAC score of zero, traditionally considered “zero risk,” were reclassified into higher-risk categories once total plaque volume was considered, confirming the presence of non-calcified plaque missed by calcium scoring alone. 30% of patients with CAC scores of 1-99 or 100-299 were moved to a higher-risk category with the addition of total plaque volume, indicating more significant plaque burden. The study also demonstrated downward classification in patients with high calcium but more modest total plaque volume, including downward classification in 27% of patients with CAC scores of 1,000 or higher. Results showed that male patients exhibited more upward reclassification, and female patients exhibited more downward reclassification, across all CAC scores. These data reinforce previously published findings that Heartflow Plaque Staging changed management in more than 50% of patients. This latest analysis provides a model for intensifying preventive therapy in patients with high total plaque volume despite zero calcium and for de-escalating in patients with high calcium but lower total plaque volume, demonstrating the value of characterizing both calcified and non-calcified disease burden. High Precision & Reproducibility (Poster 633): Validating Heartflow Plaque Analysis for Longitudinal Disease Tracking. Serial monitoring of CAD only works if measurement variability can be distinguished from true disease change. This study shows Heartflow Plaque Analysis meets this requirement, with minimal inter- and intra-observer variability in a blinded, prospective study—delivering the reproducibility clinicians need for longitudinal tracking with confidence. The study analyzed 27 coronary computed tomography angiography scans, which were blinded and evaluated three times each by three certified analysts, providing 243 independent analyses in total. The study demonstrated minimal relative variability between different qualified analysts, with coefficients of variation of 3% for total plaque volume, 6% for calcified plaque, and 4% for non-calcified plaque. Repeat analyses by the same qualified analyst proved highly consistent, with variation rates of 5% for total plaque volume, 6% for calcified plaque, and 6% for non-calcified plaque. The Fleiss’ kappa score for categorizing patients into total plaque volume-based plaque stages was 95%. This level of agreement establishes the technology as highly reliable for clinical-trial-grade serial monitoring and future tracking of disease progression over time. Real-World Scanner Transition (Poster 618): Analytical Consistency Across Conventional and Photon-Counting CT. As healthcare facilities transition from conventional Energy-Integrating Detector CT systems to next-generation Photon-Counting CT, maintaining analytical consistency is critical for clinical continuity. This retrospective, multi-center study of 12,269 patients across eight clinical sites directly tested whether Heartflow's plaque quantification, stenosis grading, and FFRCT values remain consistent across this scanner technology transition. Results showed no significant differences between Energy-Integrating Detector and Photon-Counting CT for total plaque volume, non-calcified plaque, calcified plaque, maximum stenosis grade, lowest FFRCT value and anatomy-physiology reclassification rates. The findings demonstrate that clinical sites transitioning to next-generation Photon-Counting CT can ensure comparisons using Heartflow Plaque Analysis remain valid during scanner transitions. Heartflow Plaque Analysis is the only FDA-cleared, AI-powered plaque analysis tool with a reported 95% agreement with the gold standard, intravascular ultrasound, in a prospective, international trial using blinded core lab adjudication. Heartflow Plaque Staging builds on this foundation, categorizing plaque burden into clinical risk stages based on total plaque volume, enabling clinicians to move from measurement to actionable risk stratification. The staging framework has been prospectively validated in 23,000 patients with up to 16 years of follow-up, leveraging a highly reproducible analysis suitable for serial disease monitoring and guiding individualized preventive treatment strategies. Heartflow’s technology is redefining precision cardiovascular care through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,800 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population.

Announcement • Mar 16

Heartflow, Inc. Builds Evidence Base Across The Heart Disease Care Continuum

Heartflow, Inc. announced new clinical evidence and a landmark registry launch that together advance the company's vision of transforming CAD management across every stage of the patient journey. At the American College of Cardiology (ACC) Annual Scientific Session, Heartflow is presenting new clinical evidence that further establishes AI-powered Heartflow Plaque Analysis as the leading tool for identifying high-risk patients earlier and guiding more effective medical management. Heartflow has enrolled the first patient in the NAVIGATE-PCI Registry, the first large-scale effort to evaluate the real-world impact of CT-guided percutaneous coronary intervention (PCI) planning on clinical strategy, procedural efficiency and physician confidence. The registry is evaluating how often treatment plans change when physicians use the AI-driven insights provided by Heartflow PCI Navigator compared to angiography alone. Heartflow Plaque Analysis will be featured in three ACC 2026 presentations, covering long-term validation of risk stratification, real-world comparative effectiveness in lipid management, and economic sustainability. Collectively, these data reinforce Plaque Analysis as a personalized, clinically actionable and cost-effective solution for CAD management. This cohort, based on a large-scale registry tracking over 15,000 patients, with up to 16 years of follow-up, demonstrated that Plaque Analysis is a powerful predictor of major adverse cardiovascular events (MACE), even after accounting for traditional risk factors and the severity of coronary stenosis. The findings reveal that patients with extensive plaque volume face a fourfold higher risk of such events. This robust, real-world data solidifies Heartflow Plaque Staging as the most powerful CTA-based independent predictor for personalized risk stratification, enabling clinicians to identify high-risk individuals beyond conventional metrics. This analysis, involving nearly 3,800 patients, compared patient management guided by CCTA with Plaque Analysis versus traditional stress-test-guided care over a one-year follow-up. A significantly higher portion of patients whose care was informed by Plaque Analysis initiated lipid-lowering therapy and achieved guideline-recommended LDL goals (<70 mg/dL). These findings demonstrate that Heartflow's AI-powered insights optimize medical management, pushing beyond conventional diagnostic pathways for more precise and effective treatment outcomes, regardless of traditional risk factors. The primary endpoint data from the landmark DECIDE Registry, the largest prospective registry evaluating the clinical impact of Heartflow Plaque Analysis on medical management decisions, were recently published in JACC Cardiovascular Imaging. This study demonstrated that Plaque Analysis is not only clinically impactful, but also economically sustainable. The analysis revealed that cost-effectiveness and parity with usual care are achieved in under two years with total population savings of $140 million, as incremental testing costs to prevent a single MACE fall significantly below the actual cost of treating a MACE. This research reinforces prevention as a critical value-based care strategy, highlighting how Heartflow's technology delivers substantial long-term savings and improved patient outcomes for both payers and healthcare systems. Heartflow Plaque Analysis is the only FDA-cleared, AI-powered plaque analysis tool with a reported 95% agreement with the gold standard, intravascular ultrasound (IVUS), in a prospective, international trial using blinded core lab adjudication. Heartflow Plaque Staging guides patient risk stratification based on total plaque volume, informing actionable treatment plans, simplifying decision-making and personalizing preventive treatment based on patient risk. Heartflow is expanding the Heartflow One platform with the addition of Heartflow PCI Navigator to support diagnosing, managing and guiding treatment for patients throughout the spectrum of CAD care. PCI Navigator is the only integrated, AI-driven percutaneous coronary interventions (PCI) planning tool that gives interventional cardiologists a patient-specific 3D model detailing anatomy, plaque composition, and lesion-specific physiology, all aligned to optimize potential stent placement. Heartflow introduced PCI Navigator to close the critical information gaps interventional cardiologists face before entering the cardiac catheterization lab. Commercial availability of PCI Navigator is expected in the second quarter of 2026. Heartflow’s technology is redefining precision cardiovascular care through clinically proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,400 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by ACC/AHA guidelines and supported by more than 600 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 500,000 patients worldwide. Key benefits include: Proprietary data pipeline: Built from more than 160 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible insights across diverse patient populations. Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 200 studies assessing over 365,000 patients. Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 97%. Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay. Quality system, global security and patient-data integrity compliance: Heartflow meets or exceeds leading international standards, including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001.

Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Historical stock prices
Current Share Price	US$50.75
52 Week High	US$52.22
52 Week Low	US$20.13
Beta	0
1 Month Change	2.01%
3 Month Change	49.97%
1 Year Change	54.35%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	76.52%

	HTFL	US Healthcare Services	US Market
7D	1.7%	1.6%	-0.2%
1Y	54.3%	-17.8%	11.9%

HTFL volatility
HTFL Average Weekly Movement	13.4%
Healthcare Services Industry Average Movement	10.4%
Market Average Movement	6.8%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

HTFL fundamental statistics
Market cap	US$4.41b
Earnings (TTM)	-US$118.37m
Revenue (TTM)	US$212.07m

Key profitability statistics from the latest earnings report (TTM)
HTFL income statement (TTM)
Revenue	US$212.07m
Cost of Revenue	US$42.24m
Gross Profit	US$169.83m
Other Expenses	US$288.21m
Earnings	-US$118.37m

Earnings per share (EPS)	-1.36
Gross Margin	80.08%
Net Profit Margin	-55.82%
Debt/Equity Ratio	0%

Data	Last Updated (UTC time)
Company Analysis	2026/09/20 01:38
End of Day Share Price	2026/09/18 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

HeartFlow (HTFL) Stock Overview

Rewards

Risk Analysis

Analyst Price Targets

Coronary CT Adoption And AI Platform Will Support A Stronger Long Term Outlook

Top Analyst Narratives

Coronary CT Adoption And AI Platform Will Support A Stronger Long Term Outlook

HeartFlow, Inc. Competitors

Doximity

Waystar Holding

Schrödinger

Certara

Price History & Performance

Recent News & Updates

HTFL: Clinical Evidence And AI Adoption Will Test Execution And Margin Durability

Chief Financial Officer notifies of intention to sell stock

HeartFlow, Inc. Reports One-Year Results From Independent Government-Funded FUSION Clinical Trial Demonstrating Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures

Independent Trial Shows HeartFlow FFRCT Analysis Cuts Unnecessary Heart Procedures by 44%

HeartFlow: An Impressive MedTech Growth Play

HTFL: Beat And Raise Trajectory Will Test Execution And Competitive Risks

Recent updates

HTFL: Clinical Evidence And AI Adoption Will Test Execution And Margin Durability

Chief Financial Officer notifies of intention to sell stock

HeartFlow, Inc. Reports One-Year Results From Independent Government-Funded FUSION Clinical Trial Demonstrating Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures

Independent Trial Shows HeartFlow FFRCT Analysis Cuts Unnecessary Heart Procedures by 44%

HeartFlow: An Impressive MedTech Growth Play

HTFL: Beat And Raise Trajectory Will Test Execution And Competitive Risks

New minor risk - Share price stability

HeartFlow, Inc. Raises Earnings Guidance for the Full Year 2026

HeartFlow Raises 2026 Guidance After 48% Q2 Revenue Growth and High Gross Margins

President notifies of intention to sell stock

HeartFlow, Inc. to Report Q2, 2026 Results on Aug 13, 2026

President notifies of intention to sell stock

HeartFlow Clinical Data at SCCT 2026 Underscore AI Plaque Analysis in Heart Disease Management

Heartflow to Announce Eight New Datasets from Clinical Studies Spanning More Than 36,000 Patients at the Society of Cardiovascular Computed Tomography

HeartFlow, Inc.(NasdaqGS:HTFL) dropped from Russell Small Cap Comp Value Benchmark

President notifies of intention to sell stock

HTFL: Beat And Raise Performance Will Face Sector Pressure Ahead

President notifies of intention to sell stock

Consensus EPS estimates fall by 12%, revenue upgraded

New minor risk - Profitability

HeartFlow, Inc. Raised Earnings Guidance for 2026

Companies Like HeartFlow (NASDAQ:HTFL) Are In A Position To Invest In Growth

Forecast to breakeven in 2028

HeartFlow Lifts 2026 Outlook as Q1 Revenue Jumps on Robust Product Adoption

President notifies of intention to sell stock

HeartFlow, Inc., Annual General Meeting, Jun 16, 2026

HeartFlow, Inc. to Report Q1, 2026 Results on May 14, 2026

President notifies of intention to sell stock

Chief Medical Officer & Executive VP notifies of intention to sell stock

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

HeartFlow, Inc. Provides Earnings Guidance for the Year 2026

Heartflow, Inc. Builds Evidence Base Across The Heart Disease Care Continuum

Independent Director notifies of intention to sell stock

HeartFlow, Inc. to Report Q4, 2025 Results on Mar 18, 2026

President notifies of intention to sell stock

Heartflow, Inc. Expands Gamefilm Registry to Nba and Nhl Alumni, Precisely Measuring Heart Disease Risk in Former Professional Athletes

New minor risk - Share price stability

Insufficient new directors

Heartflow, Inc. Announces Two New Analyses from Fish&Chips

Consensus EPS estimates fall by 20%, revenue upgraded

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Heartflow, Inc. Provides Earnings Guidance for Full Year 2025

Heartflow, Inc. Announces Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification

HeartFlow, Inc. to Report Q3, 2025 Results on Nov 12, 2025

Heartflow, Inc. Introduces Heartflow PCI Navigator

Heartflow, Inc. Announces FDA 510(k) Clearance and Launch of Next Generation Heartflow Plaque Analysis Platform

HeartFlow, Inc. has completed an IPO in the amount of $316.666673 million.

Shareholder Returns

Price Volatility

About the Company

HeartFlow, Inc. Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources